AI exoskeleton gives wheelchair users the freedom to walk again
For Caroline Laubach, being a Wandercraft test pilot is about more than just trying out new technology. It's about reclaiming a sense of freedom and connection that many wheelchair users miss. Laubach, a spinal stroke survivor and full-time wheelchair user, has played a key role in demonstrating the personal AI-powered prototype exoskeleton's development, and her experience highlights just how life-changing this device can be.
"When I'm in the exoskeleton, I feel more free than I do in my daily life," said Laubach. "It gives me the opportunity to walk around and talk to people at eye level. I don't have to look up at people all the time.
"It makes me feel more visible and able to connect with others. One thing I noticed right away, was how inclusive the exoskeleton would be to a wide variety of disabilities. The goal is to have disabled people able to use this exoskeleton to live their daily life out in the world; I can definitely see that happening in the future."
Laubach's story is at the heart of Wandercraft's mission: to help people move through the world with greater walking independence and upright mobility.
Wandercraft's journey began with a personal challenge. Nicolas Simon, the company's co-founder, saw his own family members struggle with mobility due to Charcot-Marie-Tooth disease, a genetic condition. As a student and robotics enthusiast, Simon wanted to create something that could help his brother and others like him walk again. Alongside Matthieu Masselin and Jean-Louis Constanza, who also had a personal connection to the cause, Simon founded Wandercraft in 2012.
Their goal was simple but ambitious: to bring advanced mobility solutions to the estimated 80 million people worldwide who rely on wheelchairs.
Wandercraft's first exoskeleton, Atalante X, is already making a difference in over 100 clinics and research centers worldwide. This device, cleared by the Food and Drug Administration (FDA) and approved in Europe, helps patients take over a million steps each month as part of their rehabilitation. It has already helped hundreds regain some mobility and independence.
But Wandercraft wanted to go further. The new Personal Exoskeleton protoype, now in clinical trials in New York and New Jersey, is designed for daily life, at home, at work, and out in the community. It uses NVIDIA AI to adapt instantly to each user's movements, providing smooth, stable walking on all sorts of surfaces, from sidewalks to carpets. Users control the exoskeleton with a joystick, making it accessible to people with a wide range of abilities.
A big part of Wandercraft's progress comes from its partnership with Nvidia. The team uses Nvidia Isaac Sim, a powerful simulation tool, to test and improve the exoskeleton in virtual environments before real-world trials. They're also exploring Nvidia's healthcare robotics and edge computing platforms to make the device smarter and more responsive.
This technology means the exoskeleton can someday keep up with everyday life, walking at a normal pace, crossing streets, and even handling stairs. As Simon puts it, "It's essential for the exoskeleton to be fast enough that it can be used in the real world. By integrating NVIDIA AI into the device, we can someday enable users to walk at an average pace, cross the road, and go up and down stairs."
Wandercraft's commitment to improving lives goes beyond just building exoskeletons. In the heart of Manhattan, the company has opened Walk in New York by Wandercraft, a state-of-the-art physical therapy practice and Atalante X walk center located at 345 Park Avenue South. This groundbreaking center is the first of its kind in the U.S. and represents a partnership between Wandercraft and licensed physical therapy professionals to help individuals with neurological conditions move more, move better and move again.
At Walk in New York, movement is truly seen as medicine. The center offers personalized screenings with licensed physical therapists, hands-free walking sessions using the Atalante X exoskeleton, and comprehensive neurorehabilitation services. Patients can experience walking again in a safe, professional environment, regardless of their trunk or upper body strength. Each therapy plan is tailored to the individual, and progress is tracked objectively to ensure the best possible outcomes.
The technology at Walk in New York goes beyond exoskeletons. The center features virtual reality systems for real-time movement feedback, mirror therapy to promote motor recovery, advanced gait analysis, and immersive environments that make rehabilitation more engaging and effective.
Walk in New York is also set to become the hub for Wandercraft's Personal Exoskeleton, where individuals will be able to receive their own devices, undergo training, and access ongoing support as this technology becomes available for everyday use. The center's focus on personalized care and innovation makes it a welcoming space for anyone interested in rediscovering mobility, whether for themselves or a loved one.
At Walk in New York, the belief is simple: movement is medicine, and everyone deserves the chance to move through life with confidence and independence.
Wandercraft is working toward FDA approval for the Personal Exoskeleton, with hopes of making it available to millions of wheelchair users in the U.S. and beyond. The company is actively recruiting participants for its clinical trials and is committed to making this technology accessible, with plans for Medicare coverage in the future.
Are you an adult 18 or older with a complete or incomplete motor SCI at or above the T6 vertebra? If so, you might be eligible for our clinical trial. To participate, you'll need a physically able companion to assist you during sessions. If you don't have someone in mind, don't worry, Wandercraft is creating a volunteer network to help connect trial participants with companions. Both patients and companions should be able to speak English or communicate well with a translator. If you meet these criteria, or if you're interested in volunteering as a companion, you can reach out to Wandercraft by emailing them at clinicaltrials@wandercraft.health
Despite all the advances in technology over the past few decades, tens of millions of people still rely on wheelchairs. Wandercraft's Personal Exoskeleton, shaped by the real-life experiences of test pilots like Laubach, is offering a new way forward, one that brings freedom, independence and a renewed sense of possibility.
Laubach's story really shows how powerful this technology can be when it is designed with real people in mind. Wandercraft's Personal Exoskeleton isn't just about robotics or AI; it's about helping people stand tall, connect with others, and live life on their own terms. Every step taken with this device brings that vision closer to reality, making the future of mobility feel more hopeful and within reach than ever before.
In what ways could AI-driven wearable robotics reshape how we think about disability and independence? Let us know by writing us at Cyberguy.com/Contact
For more of my tech tips and security alerts, subscribe to my free CyberGuy Report Newsletter by heading to Cyberguy.com/Newsletter
Follow Kurt on his social channels:
Answers to the most-asked CyberGuy questions:
New from Kurt:
Copyright 2025 CyberGuy.com. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Yili Secures Four World Dairy Innovation Awards at the 18th Global Dairy Congress
AMSTERDAM, June 23, 2025 /PRNewswire/ -- On June 18–19, the Global Dairy Congress 2025 was held in Amsterdam. At the forum, Dr. Ignatius Szeto, Assistant President of Yili Group, delivered a keynote speech titled "Innovating for a sustainable future" and shared Yili's latest innovative practices. On the opening day, the organizers unveiled the winners of the 2025 World Dairy Innovation Awards. Yili secured four World Dairy Innovation Awards and six commended Awards. Notably, Yili has claimed the World Dairy Innovation Awards for six consecutive years. Dr. Carolien van Loo, Head of Yili Innovation Center Europe, attended a roundtable forum on maternal and infant nutrition and breast milk research. Multiple star products from Yili's top infant formula brand, Pro-Kido, were featured as the Congress's officially designated products. At the Industry Leadership Forum, Dr. Ignatius Szeto systematically introduced Yili's global innovation practices across product innovation, maternal and infant nutrition, advanced dairy processing, and sustainable development. He emphasized: "Innovation is the driving force behind the sustainable prosperity of the dairy industry. Remaining consumer-centric, Yili dedicates itself to nutrition and health research across the full life cycle, keeps making core technological breakthroughs, and accelerates the commercialization of fundamental research outcomes—all of which contribute to the advancement of the global dairy sector." During the roundtable forum themed "Innovation in Pioneering a New Future for Global Maternal and Infant Health", Dr. Ignatius Szeto and Dr. Carolien van Loo engaged in in-depth discussions with experts including Jean-Christophe Kremer, Secretary-General of the International Special Dietary Foods Industries, and Richard Hall, Chair of FoodBev Media. The discussions focused on research about breast milk and maternal and infant nutrition. Dr. Carolien van Loo highlighted that Yili Innovation Center Europe, in collaboration with institutions such as Wageningen University and Donders Institute for Brain, Cognition and Behaviour, has conducted pioneering research on HMOs. Their breakthrough findings demonstrated HMOs' health benefits in enhancing immunity, protecting gut barrier function, preventing pathogen adhesion, and promoting cognitive development. The annual World Dairy Innovation Awards were announced at the event. This year, Yili Group secured four awards for its high-quality products and outstanding performance in innovation. Zhenlao Light Cream from Yijiahao Cheese won the Best Artisan Product, Joyday Crunchy Choco Lava was awarded Best Ice Cream, Yili's patented multi-enzymatic lactose-to-GOS technology: Boosting Gut Health in Qinghuo Adult Milk Powder claimed the Best Intolerance-Friendly Innovation, and Satine Carbon-Reduced Organic Milk won the Best CSR/Sustainability Initiative. Staying true to its philosophy of "No Innovation, No Future," Yili consistently increases its R&D investment to provide comprehensive nutrition solutions for consumers across the full life cycle. To date, Yili has established 15 innovation centers across Asia, Europe, and Oceania. Moving forward, Yili will continue to align its strategy with consumer needs, drive growth through technological innovation, and foster global partnerships to deliver enhanced health value for consumers worldwide, aiming to enable the sustainable prosperity of the dairy industry. View original content to download multimedia: SOURCE Yili Group Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Medscape
an hour ago
- Medscape
CMR in MINOCA Linked to Improved Diagnosis and Management
TOPLINE: In a prospective study of over 300 patients with myocardial infarction with nonobstructive coronary arteries (MINOCA), cardiovascular magnetic resonance (CMR) was associated with meaningful changes in clinical diagnosis and/or management in 63% of patients and a similar increase in diagnostic certainty. METHODOLOGY: Previous CMR studies in MINOCA have focused on radiologic yield — a limited metric that does not reflect real‐world clinical utility. Prospective data on patient care are lacking. This prospective study conducted in Australia and the UK assessed the impact of CMR on diagnosis and management in 320 patients with MINOCA (mean age, 55.6 years; 52% men) recruited between January 2019 and July 2023. Patients were included if they had a hospital admission with acute features consistent with the Fourth Universal Definition of Myocardial Infarction, no obstructive coronary artery disease on angiography, and a clinician assessment indicating acute myocardial infarction as the most likely presentation. The treating cardiologists completed a questionnaire before and after CMR to record their working diagnosis, rate diagnostic certainty on a 1-10 scale (10 = most certain), and specify intended management, including medications and follow-up testing. The primary endpoint was a composite of change in clinical diagnosis or management after CMR. TAKEAWAY: CMR was associated with a change in diagnosis or management in 63% of patients (P < .001), with diagnosis revised in 38% and management changed in 50%. Diagnostic certainty increased significantly from a median score of 6-8 after CMR (P < .001), and diagnostic confidence numerically increased in 63% of patients. The absence of coronary atheroma, a pre-CMR diagnostic certainty score ≤ 5, and early CMR (performed within 14 days of hospital presentation) independently predicted a change in diagnosis or management, with 80% of patients with all three predictors vs 40% of those with none meeting the primary outcome. Of 172 patients initially prescribed dual antiplatelet therapy, 66 (38%) had it deprescribed following CMR, yielding a number needed to test of 3. IN PRACTICE: 'Integration of CMR into diagnostic imaging pathways may be reasonable to augment clinical diagnosis and management; however, further cost-effectiveness analyses are now warranted,' the study authors wrote. SOURCE: This study was led by Adil Rajwani, PhD, of the Royal Perth Hospital, Perth, Australia. It was published online on June 13, 2025, in Heart. LIMITATIONS: The study was limited by the impracticality of conducting a bias-free randomized trial of CMR vs no CMR. It was also limited by the assessment of CMR's impact only immediately after imaging, potentially missing later clinical insights. Medication protocols were not standardized, and the limited use of additional diagnostics such as optical coherence tomography may have influenced the findings. DISCLOSURES: This study was funded by a grant from the Royal Perth Hospital Medical Research Foundation in Australia. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and prolonged PFS compared to VRd alone If approved, it would represent the fourth indication in the EU and second in the front-line setting globally Paris, June 23, 2025. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant. A final decision is expected in the coming months. Global Head, Oncology'The CHMP's recommendation represents significant progress toward our ambition for Sarclisa, addressing unmet patient needs in multiple myeloma care and making a meaningful difference in treatment outcomes at every stage of the disease across regions. If approved, this regimen would represent a new, important induction option for transplant-eligible patients, with the potential to improve long-term outcomes and deepen responses at a critical juncture in treatment.' The positive CHMP opinion is based on part one results from the two-part, double-randomized, German-speaking Myeloma Multicenter Group (GMMG)-HD7 study (clinical study identifier: NCT03617731), presented at the 2024 American Society of Hematology Annual Meeting & Exposition and published in the Journal of Clinical Oncology. GMMG-HD7 is the first phase 3 study to demonstrate a deep and rapid response with an anti-CD38-based induction regimen in transplant-eligible (TE) NDMM patients, with a higher proportion of patients with minimal residual disease (MRD) negativity benefit post-induction, alongside a significant progression-free survival (PFS) benefit from first randomization, regardless of maintenance therapy and without consolidation. Additionally, the data showed the highest post-induction and post-transplant MRD negativity rates of any CD38 monoclonal antibody using VRd as a backbone in TE NDMM. The results are part of the growing body of clinical evidence supporting the use of Sarclisa in the front-line setting and reinforce the potential of Sarclisa-VRd when used prior to transplant. Sarclisa is currently approved in three indications in the EU, across different lines of therapy in adult patients with relapsed and/or refractory (R/R) MM and with NDMM who are not eligible for transplant. About the GMMG-HD7 studyGMMG-HD7 is an investigational pivotal, randomized, open-label, multicenter, two-part phase 3 study evaluating Sarclisa in combination with VRd, also referred to as RVd (lenalidomide, bortezomib, and dexamethasone), versus VRd induction followed by post-transplant re-randomization to Sarclisa plus lenalidomide versus lenalidomide maintenance in TE NDMM patients. The GMMG-initiated study is being conducted in close collaboration with Sanofi based on jointly defined research. Sanofi provided financial support to GMMG for this study. In December 2021, Sanofi and GMMG shared results from part one, which met the primary endpoint of MRD negativity after induction therapy and before transplant in NDMM patients. The study enrolled 662 patients with TE NDMM across 67 sites in Germany. In the first part of the study, all participants were equally randomized to receive three 42-day cycles of VRd in both arms of the study, while Sarclisa was added to only one study arm. In the second part of the study, patients were re-randomized post-transplant to receive Sarclisa plus lenalidomide or lenalidomide alone as maintenance therapy. During the study, Sarclisa was administered through an intravenous infusion at a dose of 10 mg/kg once weekly for the first four weeks of cycle one, then every other week for the rest of the induction period. The GMMG-HD7 protocol defined two primary endpoints: MRD negativity following induction therapy in the first part of the study, and PFS after the second randomization post-transplant in the second part, where Sarclisa was added to lenalidomide maintenance. The latter endpoint is expected to be available at a later time. The key secondary endpoint for the first part of the study was PFS from first randomization. Additional secondary endpoints included rates of complete response after induction, and intensification, overall survival, and safety. MRD negativity was assessed by next-generation flow cytometry (sensitivity of 1x10-5) after induction. In the latest results, PFS for both arms, regardless of maintenance therapy, were measured from the first randomization. About SarclisaSarclisa (isatuximab) is approved in more than 50 countries, including in the US, EU, Japan, and China, across multiple treatment lines for MM. Based on the ICARIA-MM phase 3 study, Sarclisa is approved in the US, EU and Japan in combination with pomalidomide and dexamethasone for the treatment of patients with R/R MM who have received ≥two prior therapies, including lenalidomide and a proteasome inhibitor and have relapsed on the last therapy; this combination is also approved in China for patients who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. Based on the IKEMA phase 3 study, Sarclisa is also approved in more than 50 countries in combination with carfilzomib and dexamethasone, including in the US for the treatment of patients with R/R MM who have received one to three prior lines of therapy and in the EU for patients with MM who have received at least one prior therapy. In the US, EU, UK, and China, Sarclisa is approved in combination with VRd as a front-line treatment option in transplant-ineligible NDMM patients, based on the IMROZ phase 3 study. In Japan, Sarclisa is approved in combination with VRd as a front-line treatment option regardless of transplant eligibility. At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need. For more information on Sarclisa clinical studies, please visit About the German-speaking Myeloma Multicenter Group GMMG is the largest study group focusing on MM in Germany, with headquarters based in Heidelberg. Within the last 20+ years, the GMMG study group has performed numerous studies including five randomized, multicenter phase 3 studies with 4,000 patients enrolled from about 90 participating and cotreating centers throughout Germany. The overall goal of GMMG is to generate improved therapies for myeloma patients through the development and testing of novel and personalized, genome- and signaling driven treatment strategies. The GMMG has set itself the goal of achieving further approvals for effective antibody-based drug combinations for the first-line treatment of myeloma patients, in which antibody-based treatment regimens have been integrated into seven GMMG study concepts (CONCEPT, DANTE, DADA, HD6, HD7, HD8, HD9 and HD10). About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Le Bourhis | +33 6 75 06 43 81 | Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Léa Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Kaisserian | +33 6 47 04 12 11 | Felix Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Tarik Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans', and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi Press_ReleaseSign in to access your portfolio
